Press "Enter" to skip to content

New patent expiration for Boehringer Ingelheim drug STIOLTO RESPIMAT

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Boehringer Ingelheim drug STIOLTO RESPIMAT

Annual Drug Patent Expirations for STIOLTO+RESPIMAT
Annual Drug Patent Expirations for STIOLTO+RESPIMAT

Stiolto Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug.

This drug has one hundred and eigthy-seven patent family members in forty-seven countries.

The generic ingredient in STIOLTO RESPIMAT is olodaterol hydrochloride; tiotropium bromide. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride; tiotropium bromide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Boehringer Ingelheim drug STIOLTO RESPIMAT
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions